Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation reports developments in medical research programs focused on traumatic brain injury, PTSD, suicide ideation, dialysis-borne neuropathy and pruritus. The company’s updates describe its proprietary nasal spray approach for post-head-trauma treatment, its LDX compound, and work with Athena GTX, Athena Telemedicine Partners and scientists at Mississippi State University.
Recurring news also covers Halberd’s NeuroSense AI acquisition and behavioral intelligence platform, which combines multi-modal behavioral data with artificial intelligence for TBI research and clinical assessment. Other company updates address patent-related assets, government-contract efforts, private funding discussions, and OTC public-company communications.
Halberd Corp. (OTC PINK: HALB) announced the successful completion of a partnership with a major research university to develop compounds for its patented extracorporeal treatment for Covid-19. The contract terms are finalized, and signatures are in process, with more details to be released soon. Halberd holds exclusive rights to multiple provisional patents related to Covid-19 treatments. The company is debt-free and compliant with OTC Market reporting requirements.
Halberd Corp. (OTC PINK: HALB) provides insights into its patented extracorporeal treatment for COVID-19 in a recent response from CEO William A. Hartman. The unique process aims to remove disease antigens from bodily fluids through a method akin to kidney dialysis, using complexing agents to attract and sequester these antigens. The company also holds provisional patents for multiple methods targeting COVID-19, emphasizing its distinct approach compared to conventional treatments. As a debt-free entity, Halberd is positioned to explore revolutionary medical techniques, although it faces potential regulatory scrutiny.
Halberd Corp. (OTC PINK: HALB) announced the appointment of Edson Brito to its Scientific Advisory Board. With extensive experience in sales and business development in the pharma sector, Brito aims to facilitate the advancement of COVID-19 treatments in international markets. Chairman William Hartman expressed confidence in Brito's expertise, particularly regarding the company's research and development efforts. Halberd holds exclusive rights to multiple provisional patents for COVID-19 treatment, emphasizing its commitment to addressing the pandemic.